{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:32:46Z","timestamp":1793694766124,"version":"4.5.1"},"reference-count":177,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The ocular surface is a structure crucial to maintaining eye health and proper vision. Unfortunately, ocular surface diseases functioning as chronic epithelial defects, inflammation, impaired healing, require immediate regenerative repair treatment that can restore tissue integrity and function. Conventional therapies, such as artificial tears and topical anti-inflammatory agents, principally provide symptomatic relief without addressing the underlying biological deficits, thus leading to incomplete or delayed recovery. Therefore, blood derivatives have emerged as a promising bioactive therapy that not only lubricates but also actively promotes regeneration through the delivery of cytokines, growth factors, and vitamins naturally present in blood. Due to their properties mimicking the components of natural tears, autologous origin, biocompatibility and capacity to enhance tissue repair, they have emerged as a cornerstone in regenerative medicine. Therefore, the purpose of this review was to compare the evolution, positive aspects, and drawbacks, in order to demonstrate the molecular mechanism of action and the therapeutic efficacy of different blood derivates at treating ocular surface disease. Over time, these biologic preparations have evolved from the use of simple traditional serum-based derivatives to more advanced platelet-rich products, underscoring the evolving understanding of platelet-driven molecular and cellular mechanisms in tissue regeneration. Despite their widespread use, we would like to highlight the current limitations related to the lack of standardized preparation protocols, variability in composition, and evidence-based integration into clinical practice. Finally, this review highlights contemporary research trends and depicts future directions advancing the field. Key priorities include the establishment of standardized, reproducible preparation protocols; the development of next-generation platelet-derived concentrates and biomaterials; and the integration of multi-omics technologies to achieve comprehensive profiling of their biological and therapeutic activity. Moving toward methodological standardization and the execution of well-designed, high-quality comparative clinical trials will be essential to reinforce the scientific foundation, enhance translational potential, and ensure the clinical reliability of blood-derived therapies in modern regenerative medicine.<\/jats:p>","DOI":"10.3390\/ijms262211097","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:24:58Z","timestamp":1763375098000},"page":"11097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blood Derivatives in the Therapy of Ocular Surface Diseases"],"prefix":"10.3390","volume":"26","author":[{"given":"Piotr","family":"St\u0119pie\u0144","sequence":"first","affiliation":[{"name":"Department of Diagnostic and Microsurgery of Glaucoma, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-7417","authenticated-orcid":false,"given":"Tomasz","family":"\u017barnowski","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Microsurgery of Glaucoma, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1325-6692","authenticated-orcid":false,"given":"Dominika","family":"Wr\u00f3bel-Dudzi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Microsurgery of Glaucoma, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref_1","first-page":"4390","article-title":"The ocular surface: The challenge to enable and protect vision: The Friedenwald lecture","volume":"48","author":"Gipson","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1542-0124(12)70613-4","article-title":"Growth factors in the tear film: Role in tissue maintenance, wound healing, and ocular pathology","volume":"5","author":"Klenkler","year":"2007","journal-title":"Ocul. Surf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1350-9462(99)00007-5","article-title":"Growth factors: Importance in wound healing and maintenance of transparency of the cornea","volume":"19","author":"Imanishi","year":"2000","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","first-page":"205","article-title":"Stimulatory effects of fibronectin and EGF on migration of corneal epithelial cells","volume":"28","author":"Watanabe","year":"1987","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0161-6420(83)34512-7","article-title":"Effects of vitamin A deficiency on the ocular surface","volume":"90","author":"Sommer","year":"1983","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.addr.2017.12.018","article-title":"Blood derivatives awaken in regenerative medicine strategies to modulate wound healing","volume":"129","author":"Mendes","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/ICO.0000000000002943","article-title":"Short-term Efficacy and Safety of Biological Tear Substitutes and Topical Secretagogues for Dry Eye Disease: A Systematic Review and Network Meta-analysis","volume":"41","author":"Jongkhajornpong","year":"2022","journal-title":"Cornea"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Metheetrairut, C., Ngowyutagon, P., Tunganuntarat, A., Khowawisetsut, L., Kittisares, K., and Prabhasawat, P. (2022). Comparison of epitheliotrophic factors in platelet-rich plasma versus autologous serum and their treatment efficacy in dry eye disease. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-12879-x"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S0004-27492008000700010","article-title":"Autologous serum for ocular surface diseases","volume":"71","author":"Quinto","year":"2008","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40123-024-01082-y","article-title":"Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease","volume":"14","author":"Jongkhajornpong","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_11","first-page":"CD009327","article-title":"Autologous serum eye drops for dry eye","volume":"2","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hachana, S., and Larriv\u00e9e, B. (2022). TGF-\u03b2 Superfamily Signaling in the Eye: Implications for Ocular Pathologies. Cells, 11.","DOI":"10.3390\/cells11152336"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ogata, F.T., Verma, S., Coulson-Thomas, V.J., and Gesteira, T.F. (2024). TGF-\u03b2-Based Therapies for Treating Ocular Surface Disorders. Cells, 13.","DOI":"10.3390\/cells13131105"},{"key":"ref_14","first-page":"565","article-title":"Role of transforming growth factor Beta in corneal function, biology and pathology","volume":"10","author":"Tandon","year":"2010","journal-title":"Curr. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.61.2.28","article-title":"Fibrocytes, Wound Healing, and Corneal Fibrosis","volume":"61","author":"Wilson","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/NFO.1000151","article-title":"TGF-\u03b2-target genes are differentially regulated in corneal epithelial cells and fibroblasts","volume":"3","author":"Guo","year":"2017","journal-title":"New Front. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/08977194.2022.2074843","article-title":"An appraisal of vascular endothelial growth factor (VEGF): The dynamic molecule of wound healing and its current clinical applications","volume":"40","author":"Goswami","year":"2022","journal-title":"Growth Factors"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Di, G., Zhao, X., Qi, X., Zhang, S., Feng, L., Shi, W., and Zhou, Q. (2017). VEGF-B promotes recovery of corneal innervations and trophic functions in diabetic mice. Sci. Rep., 7.","DOI":"10.1038\/srep40582"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41392-023-01539-9","article-title":"VEGF-B prevents excessive angiogenesis by inhibiting FGF2\/FGFR1 pathway","volume":"8","author":"Lee","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2478\/abm-2021-0026","article-title":"Wound healing of the corneal epithelium: A review","volume":"15","author":"Ghafar","year":"2021","journal-title":"Asian Biomed. (Res. Rev. News)"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Peterson, J.L., and Ceresa, B.P. (2021). Epidermal Growth Factor Receptor Expression in the Corneal Epithelium. Cells, 10.","DOI":"10.3390\/cells10092409"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/bs.pmbts.2015.05.002","article-title":"Corneal Epithelial Wound Healing","volume":"134","author":"Liu","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","article-title":"The PDGF\/PDGFR pathway as a drug target","volume":"62","author":"Papadopoulos","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_25","first-page":"e737","article-title":"Human corneal fibroblast migration and extracellular matrix synthesis during stromal repair: Role played by platelet-derived growth factor-BB, basic fibroblast growth factor, and transforming growth factor-\u03b21","volume":"12","author":"Garrote","year":"2018","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108089","DOI":"10.1016\/j.exer.2020.108089","article-title":"Corneal wound healing","volume":"197","author":"Wilson","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/1570159X16666180412092859","article-title":"Nerve Growth Factor: Early Studies and Recent Clinical Trials","volume":"16","author":"Rocco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3892\/etm.2021.10031","article-title":"Role of NGF and its receptors in wound healing (Review)","volume":"21","author":"Liu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00592-010-0227-z","article-title":"The IGF system","volume":"48","author":"Annunziata","year":"2011","journal-title":"Acta Diabetol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Stuard, W.L., Titone, R., and Robertson, D.M. (2020). The IGF\/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00024"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Farooq, M., Khan, A.W., Kim, M.S., and Choi, S. (2021). The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration. Cells, 10.","DOI":"10.3390\/cells10113242"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.preteyeres.2015.07.002","article-title":"Progress in corneal wound healing","volume":"49","author":"Ljubimov","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2174\/1389450116666151019100216","article-title":"Substance P and its Inhibition in Ocular Inflammation","volume":"17","author":"Bignami","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_35","first-page":"35","article-title":"The Activity of Substance P (SP) on the Corneal Epithelium","volume":"1","author":"Kopel","year":"2023","journal-title":"J. Clin. Transl. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yang, L., Sui, W., Li, Y., Qi, X., Wang, Y., Zhou, Q., and Gao, H. (2016). Substance P Inhibits Hyperosmotic Stress-Induced Apoptosis in Corneal Epithelial Cells through the Mechanism of Akt Activation and Reactive Oxygen Species Scavenging via the Neurokinin-1 Receptor. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149865"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/mol.115.101014","article-title":"Substance P Enhances Keratocyte Migration and Neutrophil Recruitment through Interleukin-8","volume":"89","author":"Zhou","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"110179","DOI":"10.1016\/j.exer.2024.110179","article-title":"Role of vitamin A on the ocular surface","volume":"250","author":"Ge","year":"2025","journal-title":"Exp. Eye Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ncp.10420","article-title":"Vitamin A and Wound Healing","volume":"34","author":"Zinder","year":"2019","journal-title":"Nutr. Clin. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1111\/j.1755-3768.2012.02496.x","article-title":"The wound healing effects of vitamin A eye drops after a corneal alkali burn in rats","volume":"90","author":"Kim","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/tvst.9.6.22","article-title":"Quantification of Growth Factors and Fibronectin in Diverse Preparations of Platelet-Rich Plasma for the Treatment of Ocular Surface Disorders (E-PRP)","volume":"9","author":"Rodriguez","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.exer.2006.06.008","article-title":"Promotion by fibronectin of collagen gel contraction mediated by human corneal fibroblasts","volume":"83","author":"Liu","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archopht.1975.01010020815015","article-title":"Clinical experience with a mobile ocular perfusion pump","volume":"93","author":"Ralph","year":"1975","journal-title":"Arch. Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.1780270415","article-title":"Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca","volume":"27","author":"Fox","year":"1984","journal-title":"Arthritis Rheum."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bjo.83.4.390","article-title":"Treatment of dry eye by autologous serum application in Sj\u00f6gren\u2019s syndrome","volume":"83","author":"Tsubota","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0161-6420(99)90412-8","article-title":"Treatment of persistent corneal epithelial defect by autologous serum application","volume":"106","author":"Tsubota","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","article-title":"Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease","volume":"88","author":"Noble","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wr\u00f3bel-Dudzi\u0144ska, D., Przekora, A., Kazimierczak, P., \u0106wikli\u0144ska-Haszcz, A., Kosior-Jarecka, E., and \u017barnowski, T. (2023). The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093126"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4103\/IJO.IJO_2756_22","article-title":"Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines","volume":"71","author":"Vazirani","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00417-004-1106-5","article-title":"An optimised protocol for the production of autologous serum eyedrops","volume":"243","author":"Liu","year":"2005","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/00003226-200111000-00005","article-title":"Controlled study of the use of autologous serum in dry eye patients","volume":"20","author":"Tananuvat","year":"2001","journal-title":"Cornea"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2004.08.040","article-title":"The effect of autologous serum eyedrops in the treatment of severe dry eye disease: A prospective randomized case-control study","volume":"139","author":"Kojima","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/02713683.2012.674609","article-title":"Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome","volume":"37","author":"Urzua","year":"2012","journal-title":"Curr. Eye Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00417-014-2599-1","article-title":"The efficacy of autologous serum eye drops for severe dry eye syndrome: A randomized double-blind crossover study","volume":"252","author":"Celebi","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.12998\/wjcc.v11.i28.6774","article-title":"Randomized controlled trial on the efficacy and safety of autologous serum eye drops in dry eye syndrome","volume":"11","author":"Zheng","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/ICO.0b013e31817f3a0e","article-title":"Autologous serum eye drops for thetreatment of dry eye diseases","volume":"27","author":"Kojima","year":"2008","journal-title":"Cornea"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/02713683.2012.720340","article-title":"Comparison of autologous serum eye drops with different diluents","volume":"38","author":"Cho","year":"2013","journal-title":"Curr. Eye Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.4103\/IJO.IJO_2684_22","article-title":"Comparative evaluation of effectiveness of twenty versus fifty percent autologous serum eye drops in treatment of dry eye","volume":"71","author":"Kumari","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/vox.12502","article-title":"Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Serum eye drops: A survey of international production methods","volume":"112","author":"Marks","year":"2017","journal-title":"Vox Sang."},{"key":"ref_61","first-page":"292","article-title":"Stability of Growth Factors in Autologous Serum Eyedrops After Long-Term Storage","volume":"41","author":"Rivas","year":"2016","journal-title":"Curr. Eye Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14712\/fb2022068020045","article-title":"Time and Temperature Stability of TGF-\u03b21, EGF and IGF-1 in 20% and 100% Human Serum","volume":"68","author":"Jirsova","year":"2022","journal-title":"Folia Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajo.2020.01.027","article-title":"Lyophilized Autologous Serum Eyedrops: Experimental and Comparative Study","volume":"213","author":"Rivas","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.0958-7578.2005.00559.x","article-title":"Topical treatment of ocular surface defects: Comparison of the epitheliotrophic capacity of fresh frozen plasma and serum on corneal epithelial cells in an in vitro cell culture model","volume":"15","author":"Hartwig","year":"2005","journal-title":"Transfus. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3928\/1081-597X-20060101-13","article-title":"Autologous serum eye drops for dry eye after LASIK","volume":"22","author":"Toda","year":"2006","journal-title":"J. Refract. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"931","DOI":"10.21873\/invivo.11016","article-title":"Effect of Autologous Serum Eye Drops in Patients with Sj\u00f6gren Syndrome-related Dry Eye: Clinical and In Vivo Confocal Microscopy Evaluation of the Ocular Surface","volume":"30","author":"Semeraro","year":"2016","journal-title":"Vivo"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/02713683.2016.1255758","article-title":"Comparison of Autologous Serum Versus Preservative Free Artificial Tear in Patients with Dry Eyes Due to Systemic Isotretinoin Therapy","volume":"42","year":"2017","journal-title":"Curr. Eye Res."},{"key":"ref_68","first-page":"200","article-title":"Serum eye drops for the treatment of ocular surface diseases: A systematic review and meta-analysis","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000505630","article-title":"Autologous Serum Eye Drops versus Artificial Tear Drops for Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"63","author":"Wang","year":"2020","journal-title":"Ophthalmic Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/OPX.0000000000002042","article-title":"Autologous Serum Eye Drops for Dry Eye: Systematic Review","volume":"100","author":"Quan","year":"2023","journal-title":"Optom. Vis. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, N., Ge, Z., and Li, F. (2024). Blood component therapy for dry eye disease: A systematic review and network meta-analysis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1500160"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mederle, A.L., Andrei, D., Ghenciu, L.A., Stoicescu, E.R., Iacob, R., and Ha\u0163egan, O.A. (2025). Comparative Efficacy of Platelet-Rich Plasma, Autologous Serum, and Artificial Tears in Dry Eye Disease: A Systematic Review and Meta-Analysis. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092316"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/ICO.0b013e3181a2a7f6","article-title":"Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects","volume":"28","author":"Jeng","year":"2009","journal-title":"Cornea"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Lekhanont, K., Jongkhajornpong, P., Choubtum, L., and Chuckpaiwong, V. (2013). Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery. BioMed Res. Int., 2013, Erratum in BioMed Res. Int. 2014, 2014, 595973.","DOI":"10.1155\/2014\/595973"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lekhanont, K., Jongkhajornpong, P., Anothaisintawee, T., and Chuckpaiwong, V. (2016). Undiluted Serum Eye Drops for the Treatment of Persistent Corneal Epitheilal Defects. Sci. Rep., 6.","DOI":"10.1038\/srep38143"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/ICL.0000000000000277","article-title":"Evaluation of the Role of Umbilical Cord Serum and Autologous Serum Therapy in Reepithelialization After Keratoplasty: A Randomized Controlled Clinical Trial","volume":"43","author":"Kamble","year":"2017","journal-title":"Eye Contact Lens"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.clae.2016.06.003","article-title":"Therapeutic outcomes of combined topical autologous serum eye drops with silicone-hydrogel soft contact lenses in the treatment of corneal persistent epithelial defects: A preliminary study","volume":"39","author":"Lee","year":"2016","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Chen, Y.M., Wang, W.Y., Lin, Y.C., Tsai, S.H., and Lou, Y.T. (2022). Use of Autologous Serum Eye Drops with Contact Lenses in the Treatment of Chemical Burn-Induced Bilateral Corneal Persistent Epithelial Defects. BioMed Res. Int., 2022.","DOI":"10.1155\/2022\/6600788"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00417-018-4068-8","article-title":"Application of autologous serum eye drops after pterygium surgery: A prospective study","volume":"256","author":"Sul","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/cxo.12574","article-title":"Autologous serum eye-drops and enhanced epithelial healing time after photorefractive keratectomy","volume":"101","author":"Akcam","year":"2018","journal-title":"Clin. Exp. Optom."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/OPX.0000000000001500","article-title":"The Use of Autologous Serum Eye Drops after Epithelium-off Corneal Collagen Crosslinking","volume":"97","author":"Kirgiz","year":"2020","journal-title":"Optom. Vis. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/ICO.0000000000002264","article-title":"The Use of Autologous Serum to Reverse Severe Contact Lens-induced Limbal Stem Cell Deficiency","volume":"39","author":"Yeh","year":"2020","journal-title":"Cornea"},{"key":"ref_83","first-page":"2623","article-title":"Efficacy of treatments for neurotrophic keratopathy: A systematic review and meta-analysis","volume":"260","author":"Roumeau","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_84","first-page":"576521","article-title":"Limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis","volume":"2011","author":"Welder","year":"2011","journal-title":"Case Rep. Ophthalmol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/archopht.1988.01060140587028","article-title":"Immunoglobulin deposition in the cornea after application of autologous serum","volume":"106","author":"McDonnell","year":"1988","journal-title":"Arch. Ophthalmol."},{"key":"ref_86","first-page":"71","article-title":"Fulminant bilateral Haemophilus influenzae keratitis in a patient with hypovitaminosis A treated with contaminated autologous serum","volume":"5","author":"Udaondo","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ajo.2006.04.017","article-title":"Autologous serum for the treatment of corneal epithelial abrasions in diabetic patients undergoing vitrectomy","volume":"142","author":"Schulze","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/bjophthalmol-2013-304801","article-title":"Comparative role of 20% cord blood serum and 20% autologous serum in dry eye associated with Hansen\u2019s disease: A tear proteomic study","volume":"99","author":"Mukhopadhyay","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_89","first-page":"e396","article-title":"Autologous versus allogeneic versus umbilical cord sera for the treatment of severe dry eye disease: A double-blind randomized clinical trial","volume":"100","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/ICO.0000000000003795","article-title":"The Effect of Autologous Serum Tears 50% on the Ocular Surface of Patients With Severe Dry Eye Disease due to Sjogren Syndrome: A Prospective, Double-Blind, Randomized, Controlled, Contralateral Eye Study","volume":"44","author":"Bachtalia","year":"2025","journal-title":"Cornea"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"103912","DOI":"10.1016\/j.transci.2024.103912","article-title":"Correlation between serum cytokine levels and the effect of allogeneic serum-based eye drops","volume":"63","author":"Chmielewska","year":"2024","journal-title":"Transfus. Apher. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jtos.2020.02.011","article-title":"The Role of Multisystem Disease in Composition of Autologous Serum tears and ocular surface symptom improvement","volume":"18","author":"Ripa","year":"2020","journal-title":"Ocul. Surf."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00417-015-3056-5","article-title":"Comparison of epitheliotrophic factors in autologous serum eyedrops from sera of chronic renal failure patients vs. normal controls","volume":"253","author":"Kang","year":"2015","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-2008-1027199","article-title":"Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis","volume":"225","author":"Harloff","year":"2008","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/aos.12386","article-title":"Ready-made allogeneic ABO-specific serum eye drops: Production from regular male blood donors, clinical routine, safety and efficacy","volume":"92","author":"Nielsen","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/aos.14788","article-title":"Allogeneic and autologous serum eye drops: A pilot double-blind randomized crossover trial","volume":"99","author":"Verbakel","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/vox.13413","article-title":"Eye drops of human origin-Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies","volume":"118","author":"Gabriel","year":"2023","journal-title":"Vox Sang."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Vo\u00df, S., Behrmann, T., and Reichl, S. (2023). Development of In Vitro Dry Eye Models to Study Proliferative and Anti-Inflammatory Effects of Allogeneic Serum Eye Drops. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021567"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.eye.6703079","article-title":"Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect","volume":"23","author":"Chiang","year":"2009","journal-title":"Eye"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/jop.2012.0002","article-title":"Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease","volume":"28","author":"Na","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1038\/s41433-021-01560-8","article-title":"Patient-reported outcome measures for a large cohort of serum eye drops recipients in the UK","volume":"35","author":"Lomas","year":"2021","journal-title":"Eye"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21873\/invivo.12310","article-title":"Regenerative Therapy Using Umbilical Cord Serum","volume":"35","author":"Maharajan","year":"2021","journal-title":"Vivo"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.ophtha.2006.12.014","article-title":"Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis","volume":"114","author":"Yoon","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/01.ico.0000183484.85636.b6","article-title":"Application of umbilical cord serum eyedrops for the treatment of dry eye syndrome","volume":"25","author":"Yoon","year":"2006","journal-title":"Cornea"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.18502\/jovr.v15i2.6732","article-title":"Topical Umbilical Cord Serum for Corneal Epithelial Defects after Diabetic Vitrectomy","volume":"15","author":"Moradian","year":"2020","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/bjo.87.11.1312","article-title":"Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects","volume":"87","author":"Vajpayee","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3341\/kjo.2005.19.3.174","article-title":"Therapeutic effect of umbilical cord serum eyedrops for persistent corneal epithelial defect","volume":"19","author":"Yoon","year":"2005","journal-title":"Korean J. Ophthalmol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1705566","article-title":"Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease","volume":"39","author":"Yoon","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.2147\/OPTH.S385078","article-title":"Treatment of Severe Dry Eye in Stevens-Johnson Syndrome with Umbilical Cord Serum Eye Drops","volume":"16","author":"Susiyanti","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/ICO.0000000000002005","article-title":"In Vivo Confocal Microscopy Automated Morphometric Analysis of Corneal Subbasal Nerve Plexus in Patients With Dry Eye Treated With Different Sources of Homologous Serum Eye Drops","volume":"38","author":"Giannaccare","year":"2019","journal-title":"Cornea"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/bjophthalmol-2019-314859","article-title":"Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: A multicentre randomised cross over clinical trial","volume":"104","author":"Campos","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/jop.2022.0107","article-title":"Therapeutic Profile of Human Umbilical Cord Blood Serum and Autologous Serum Therapies in Treatment of Ocular Surface Disorders: A Pilot Study","volume":"39","author":"Kumar","year":"2023","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1167\/iovs.09-4170","article-title":"Evaluation of umbilical cord serum therapy in acute ocular chemical burns","volume":"52","author":"Sharma","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2016.05.010","article-title":"Comparison of Amniotic Membrane Transplantation and Umbilical Cord Serum in Acute Ocular Chemical Burns: A Randomized Controlled Trial","volume":"168","author":"Sharma","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008505-200110000-00002","article-title":"Platelet-rich plasma (PRP): What is PRP and what is not PRP?","volume":"10","author":"Marx","year":"2001","journal-title":"Implant Dent."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0974-2077.150734","article-title":"Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author\u2019s Perspective","volume":"7","author":"Dhurat","year":"2014","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.joms.2003.12.003","article-title":"Platelet-rich plasma: Evidence to support its use","volume":"62","author":"Marx","year":"2004","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1111\/aos.12710","article-title":"Autologous serum and plasma rich in growth factors in ophthalmology: Preclinical and clinical studies","volume":"93","author":"Anitua","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000477353","article-title":"A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification","volume":"4","author":"Alves","year":"2018","journal-title":"Skin Appendage Disord."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ophtha.2006.10.044","article-title":"Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers","volume":"114","author":"Alio","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/ICO.0b013e3182114661","article-title":"Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury","volume":"31","author":"Panda","year":"2012","journal-title":"Cornea"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3928\/1081597X-20130129-04","article-title":"Effect of platelet-rich plasma in nerve regeneration after LASIK","volume":"29","author":"Javaloy","year":"2013","journal-title":"J. Refract. Surg."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/bjophthalmol-2018-312072","article-title":"Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye","volume":"103","author":"Avila","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_124","first-page":"e170","article-title":"Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma","volume":"97","author":"Molina","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kamiya, K., Takahashi, M., and Shoji, N. (2021). Effect of Platelet-Rich Plasma on Corneal Epithelial Healing after Phototherapeutic Keratectomy: An Intraindividual Contralateral Randomized Study. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/5752248"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Kang, M.J., Lee, J.H., Hwang, J., and Chung, S.H. (2023). Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sj\u00f6gren\u2019s syndrome: A randomized trial. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-46671-2"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1167\/iovs.11-7340","article-title":"In vitro effects of three blood derivatives on human corneal epithelial cells","volume":"53","author":"Freire","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102091","DOI":"10.1016\/j.clae.2023.102091","article-title":"Platelet-rich plasma for treating dry eye disease\u2014A systematic review and meta-analysis","volume":"47","author":"Owusu","year":"2024","journal-title":"Cont. Lens Anterior Eye"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4274\/tjo.galenos.2025.47717","article-title":"Comparison of 20% Autologous Platelet-Rich Plasma Versus Conventional Treatment in Moderate to Severe Dry Eye Patients","volume":"55","author":"Sachan","year":"2025","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Mohammed, M.A., Allam, I.Y., Shaheen, M.S., Lazreg, S., and Doheim, M.F. (2022). Lacrimal gland injection of platelet rich plasma for treatment of severe dry eye: A comparative clinical study. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02554-0"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/ICO.0b013e3181a81820","article-title":"Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects","volume":"29","author":"Morales","year":"2010","journal-title":"Cornea"},{"key":"ref_132","first-page":"222","article-title":"Plasma rich in growth factors for the treatment of dry eye after refractive surgery","volume":"34","author":"Riestra","year":"2018","journal-title":"J. Refract. Surg."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/17460751.2025.2544486","article-title":"Sustained long-term benefits of autologous subconjunctival platelet-rich plasma injections for severe dry eye disease","volume":"20","author":"Mora","year":"2025","journal-title":"Regen. Med."},{"key":"ref_134","first-page":"e51794","article-title":"Evaluation of the Use of Highly Concentrated Autologous Platelet-Rich Plasma and Platelet-Rich Fibrin Membrane to Improve the Outcome in the Management of Severe Dry Eye Disease, Corneal Neurotrophic Ulcer and Corneal Burn","volume":"16","author":"Hassan","year":"2024","journal-title":"Cureus"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exer.2016.08.012","article-title":"PRGF exerts more potent proliferative and anti-inflammatory effects than autologous serum on a cell culture inflammatory model","volume":"151","author":"Anitua","year":"2016","journal-title":"Exp. Eye Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/02713683.2023.2173237","article-title":"Beneficial Effects of Plasma Rich in Growth Factors (PRGF) Versus Autologous Serum and Topical Insulin in Ocular Surface Cells","volume":"48","author":"Anitua","year":"2023","journal-title":"Curr. Eye Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2015.02.016","article-title":"Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts","volume":"135","author":"Anitua","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/ICO.0b013e31820d86d6","article-title":"Efficacy of plasma rich in growth factors for the treatment of dry eye","volume":"30","author":"Morales","year":"2011","journal-title":"Cornea"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000444496","article-title":"Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye","volume":"56","author":"Riestra","year":"2016","journal-title":"Ophthalmic Res."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Lozano-Sanroma, J., Barros, A., Alcalde, I., Alvarado-Villacorta, R., S\u00e1nchez-\u00c1vila, R.M., Queiruga-Pi\u00f1eiro, J., Cueto, L.F., Anitua, E., and Merayo-Lloves, J. (2024). Efficacy and Safety of Plasma Rich in Growth Factor in Patients with Congenital Aniridia and Dry Eye Disease. Diseases, 12.","DOI":"10.3390\/diseases12040076"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000487951","article-title":"Plasma Rich in Growth Factors for the Treatment of Dry Eye after LASIK Surgery","volume":"60","author":"Fernandez","year":"2018","journal-title":"Ophthalmic Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The Effect of Immunologically Safe Plasma Rich in Growth Factor Eye Drops in Patients with Sj\u00f6gren Syndrome","volume":"33","author":"Riestra","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1120672118818943","article-title":"Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases","volume":"30","author":"Muruzabal","year":"2020","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10792-017-0582-7","article-title":"Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops","volume":"38","author":"Riestra","year":"2018","journal-title":"Int. Ophthalmol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Wang, M., Yennam, S., and Pflugfelder, S. (2022). Initial experiences using plasma rich in growth factors to treat keratoneuralgia. Front. Med., 9.","DOI":"10.3389\/fmed.2022.946828"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/OPTH.S252253","article-title":"Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis","volume":"14","author":"Orive","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"ref_147","first-page":"97","article-title":"Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma","volume":"11","author":"Muruzabal","year":"2018","journal-title":"Int. Med. Case Rep. J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jtos.2022.04.007","article-title":"A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America","volume":"25","author":"Soifer","year":"2022","journal-title":"Ocul. Surf."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/ICO.0000000000002519","article-title":"Short- and Long-Term Stability of Plasma Rich in Growth Factors Eye Drops","volume":"40","author":"Anitua","year":"2021","journal-title":"Cornea"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.2147\/OPTH.S265701","article-title":"Human Platelets and Derived Products in Treating Ocular Surface Diseases\u2014A Systematic Review","volume":"14","author":"You","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.9.4.24","article-title":"Characteristics of Platelet Lysate Compared to Autologous and Allogeneic Serum Eye Drops","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Huang, C.J., Sun, Y.C., Christopher, K., Pai, A.S., Lu, C.J., Hu, F.R., Lin, S.Y., and Chen, W.L. (2017). Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171008"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"108613","DOI":"10.1016\/j.exer.2021.108613","article-title":"Effects of human platelet lysate on the growth of cultured human corneal endothelial cells","volume":"208","author":"Petsoglou","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Widyaningrum, R., Burnouf, T., Nebie, O., Delila, L., and Wang, T.J. (2021). A purified human platelet pellet lysate rich in neurotrophic factors and antioxidants repairs and protects corneal endothelial cells from oxidative stress. Biomed. Pharmacother., 142.","DOI":"10.1016\/j.biopha.2021.112046"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2016.221","article-title":"Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD","volume":"52","author":"Pezzotta","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2016.05.023","article-title":"A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease","volume":"22","author":"Zallio","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bmt.2012.64","article-title":"Autologous platelet lysate for treatment of refractory ocular GVHD","volume":"47","author":"Pezzotta","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"100176","DOI":"10.1016\/j.xops.2022.100176","article-title":"A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease","volume":"2","author":"Sugar","year":"2022","journal-title":"Ophthalmol. Sci."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Fea, A.M., Aragno, V., Testa, V., Machetta, F., Parisi, S., D\u2019Antico, S., Spinetta, R., Fusaro, E., and Grignolo, F.M. (2016). The Effect of Autologous Platelet Lysate Eye Drops: An In Vivo Confocal Microscopy Study. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/8406832"},{"key":"ref_160","first-page":"107","article-title":"Blood components for topical use in tissue regeneration: Evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms","volume":"8","author":"Geremicca","year":"2010","journal-title":"Blood Transfus."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s10792-018-0968-1","article-title":"Platelet lysate promotes re-epithelialization of persistent epithelial defects: A pilot study","volume":"39","author":"Jafar","year":"2019","journal-title":"Int. Ophthalmol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.3390\/cimb44100303","article-title":"Evaluation of the Regenerative Potential of Platelet-Lysate and Platelet-Poor Plasma Derived from the Cord Blood Units in Corneal Wound Healing Applications: An In Vitro Comparative Study on Corneal Epithelial Cells","volume":"44","author":"Mallis","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_163","first-page":"347","article-title":"Clinical evaluation of allogeneic eye drops from cord blood platelet lysate","volume":"19","author":"Samarkanova","year":"2021","journal-title":"Blood Transfus."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1080\/09273948.2024.2322012","article-title":"Effect of Topical Recombinant Human Nerve Growth Factor on Corneal Epithelial Regeneration in Refractory Epithelial Keratopathy","volume":"32","author":"Dai","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.4239\/wjd.v15.i6.1234","article-title":"Efficacy of recombinant human epidermal growth factor plus sodium hyaluronate eye drops in diabetic dry eye post-cataract surgery","volume":"15","author":"Li","year":"2024","journal-title":"World J. Diabetes"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/ICO.0000000000003091","article-title":"Lacripep for the Treatment of Primary Sj\u00f6gren-Associated Ocular Surface Disease: Results of the First-In-Human Study","volume":"42","author":"Tauber","year":"2023","journal-title":"Cornea"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1007\/s40123-025-01253-5","article-title":"Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China","volume":"14","author":"Li","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13023-022-02236-6","article-title":"Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: A novel cure for a rare degenerative corneal disease?","volume":"17","author":"Bruscolini","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_170","first-page":"336","article-title":"Human recombinant epidermal growth factor in experimental corneal wound healing","volume":"32","author":"Brazzell","year":"1991","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Yoo, H., Yoon, S., Jang, I.-J., Yu, K.-S., Hyon, J.Y., Hwang, J., Hwang, I., Sunwoo, J., and Chung, J.-Y. (2022). Safety, Tolerability, and Serum\/Tear Pharmacokinetics of Human Recombinant Epidermal Growth Factor Eyedrops in Healthy Subjects. Pharmaceuticals, 15.","DOI":"10.22541\/au.165538447.75302769\/v1"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-3148.2011.01072.x","article-title":"Low-cost protocol for the production of autologous serum eye drops by blood collection and processing centres for the treatment of ocular surface diseases","volume":"21","author":"Partal","year":"2011","journal-title":"Transfus. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/eye.2017.118","article-title":"Fingerprick autologous blood: A novel treatment for dry eye syndrome","volume":"31","author":"Than","year":"2017","journal-title":"Eye"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/ICO.0000000000002230","article-title":"Finger-Prick Autologous Blood in the Treatment of Persistent Corneal Epithelial Defects","volume":"39","author":"Balal","year":"2020","journal-title":"Cornea"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.2147\/OPTH.S384586","article-title":"Finger-Prick Autologous Blood (FAB) Eye Drops for Dry Eye Disease: Single Masked Multi-Centre Randomised Controlled Trial","volume":"16","author":"Hassan","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","article-title":"TFOS DEWS III: Management and Therapy","volume":"279","author":"Jones","year":"2025","journal-title":"Am. J. Ophthalmol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/22\/11097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:34:34Z","timestamp":1763375674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/22\/11097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":177,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ijms262211097"],"URL":"https:\/\/doi.org\/10.3390\/ijms262211097","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}